Cisplatin-DNA damage in p21WAF1/Cip1 deficient mouse keratinocytes exposed to cisplatin

Mutagenesis

Volumn 22, Issue 1, 2007, Pages 49-54

  Van Gijssel, Hilde E ^a,c   Leil, Tarek A ^a,d   Weinberg, Wendy C ^b   Divi, Rao L ^a   Olivero, Ofelia A ^a   Poirier, Miriam C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Valley City State University   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; DNA; MESSENGER RNA;

ANALYSIS OF VARIANCE; ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DRUG EXPOSURE; GENE EXPRESSION; HETEROZYGOTE; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; WILD TYPE;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; CELL CYCLE; CELL LINE; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA ADDUCTS; DNA DAMAGE; GENE DOSAGE; KERATINOCYTES; MICE; MICE, KNOCKOUT; TIME FACTORS;

EID: 33846111815     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gel050     Document Type: Article

References (33)

1. Shivji,M.K., Ferrari,E., Ball,K., Hubscher,U. and Wood,R.D. (1998) Resistance of human nucleotide excision repair synthesis in vitro top21Cdn1. Oncogene, 17, 2827-2838.
2. el Deiry,W.S., Tokino,T., Velculescu,V.E., Levy,D.B., Parsons,R., Trent,J.M., Lin,D., Mercer,W.E., Kinzler,K.W. and Vogelstein,B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
3. Weinberg,W.C. and Denning,M.F. (2002) P21Waf1 control of epithelial cell cycle and cell fate. Crit. Rev. Oral Biol. Med., 13, 453-464.
4. Gartel,A.L., Serfas,M.S. and Tyner,A.L. (1996) p21-negative regulator of the cell cycle. Proc. Soc. Exp. Biol. Med., 213, 138-149.
5. Harper,J.W., Adami,G.R., Wei,N., Keyomarsi,K. and Elledge,S.J. (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805-816.
6. Wani,M.A., Wani,G., Yao,J., Zhu,Q. and Wani,A.A. (2002) Human cells deficient in p53 regulated p21(waf1/cip1) expression exhibit normal nucleotide excision repair of UV-induced DNA damage. Carcinogenesis, 23, 403-410.
7. Adimoolam,S., Lin,C.X. and Ford,J.M. (2001) The p53-regulated cyclindependent kinase inhibitor, p21 (cip1, waf1, sdi1), is not required for global genomic and transcription-coupled nucleotide excision repair of UV-induced DNA photoproducts. J. Biol. Chem., 276, 25813-25822.
8. Wani,M.A., El Mahdy,M.A., Hamada,F.M., Wani,G., Zhu,Q., Wang,Q.E. and Wani,A.A. (2002) Efficient repair of bulky anti-BPDE DNA adducts from non-transcribed DNA strand requires functional p53 but not p21(waf1/cip1) and pRb. Mutat. Res., 505, 13-25.
9. Stivala,L.A., Riva,F., Cazzalini,O., Savio,M. and Prosperi,E. (2001) p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites. Oncogene, 20, 563-570.
10. Smith,M.L., Ford,J.M., Hollander,M.C., Bortnick,R.A., Amundson,S.A., Seo,Y.R., Deng,C.X., Hanawalt,P.C. and Fornace,A.J.,Jr (2000) p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol. Cell. Biol., 20, 3705-3714.
11. Fan,S., Chang,J.K., Smith,M.L., Duba,D., Fornace,A.J.,Jr and O'Connor,P.M. (1997) Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene, 14, 2127-2136.
12. Pan,Z.Q., Reardon,J.T., Li,L., Flores-Rozas,H., Legerski,R., Sancar,A. and Hurwitz,J. (1995) Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J. Biol. Chem., 270, 22008-22016.
13. McDonald,E.R.,III, Wu,G.S., Waldman,T. and el Deiry,W.S. (1996) Repair Defect in p21 WAF1/CIP1 -/- human cancer cells. Cancer Res., 56, 2250-2255.
14. Cooper,M.P., Balajee,A.S. and Bohr,V.A. (1999) The C-terminal domain of p21 inhibits nucleotide excision repair in vitro and in vivo. Mol. Biol. Cell, 10, 2119-2129.
15. Bendjennat,M., Boulaire,J., Jascur,T., Brickner,H., Barbier,V., Sarasin,A., Fotedar,A. and Fotedar,R. (2003) UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell, 114, 599-610.
16. Johnson,S.W., Stevenson,J.P. and O'Dwyer,P.J. (2001) Cisplatin and its analogues. In DeVita,V.T., Hellman,S. and Rosenberg,S.A. (eds), Cancer Principles & Practice of Oncology. Lippincott Williams & Wilkins, Philadelphia, pp. 376.
17. Zhang,Z. and Poirier,M.C. (1997) Cisplatin-DNA adduct determination in the hepatic albumin gene as compared to whole genomic DNA. Chem. Res. Toxicol., 10, 971-977.
18. Deng,C., Zhang,P., Harper,J.W., Elledge,S.J. and Leder,P. (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 82, 675-684.
19. Weinberg,W.C., Montano,N.E. and Deng,C. (1997) Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis. Oncogene, 15, 685-690.
20. Azzoli,C.G., Sagar,M., Wu,A., Lowry,D., Hennings,H., Morgan,D.L. and Weinberg,W.C. (1998) Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. Mol. Carcinog., 21, 50-61.
21. Dlugosz,A.A., Glick,A.B., Tennenbaum,T., Weinberg,W.C. and Yuspa,S.H. (1995) Isolation and utilization of epidermal keratinocytes for oncogene research. Methods Enzymol., 254, 3-20.
22. Divi,R.L., Beland,F.A., Fu,P.P., Von Tungeln,L.S., Schoket,B., Camara,J., Rothman,N., Sinha,R. and Poirier,M.C. (2002) Highly-sensitive chemiluminescence immunoassay for benzo(a)pyrene-DNA adducts: validation by comparison with other methods, and use in human biomonitoring. Carcinogenesis, 12, 2043-2049.
23. Divi,R.L., Osborne,M.R., Hewer,A., Phillips,D.H. and Poirier,M.C. (1999) Tamoxifen-DNA adduct formation in rat liver determined by immunoassay and 32P-postlabeling. Cancer Res., 59, 4829-4833.
24. Giurgiovich,A.J., Diwan,B.A., Lee,K.B., Anderson,L.M., Rice,J.M. and Poirier, M.C. (1996) Cisplatin-DNA adduct formation in maternal and fetal rat tissues after transplacental cisplatin exposure. Carcinogenesis, 17, 1665-1669.
25. Shamkhani,H., Anderson,L.M., Henderson,C.E., Moskal,T.J., Runowicz,C.D., Dove,L.F., Jones,A.B., Chaney,S.G., Rice,J.M. and Poirier,M.C. (1994) DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy. Reprod. Toxicol., 8, 207-216.
26. WAF1 in regulating the G1 and G2/M checkpoints in ultraviolet irradiated keratinocytes. J. Invest. Dermatol., 119, 513-521.
27. Hwang,B.J., Ford,J.M., Hanawalt,P.C. and Chu,G. (1999) Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc. Natl Acad. Sci. USA, 96, 424-428.
28. Ford,J.M. and Hanawalt,P.C. (1997) Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem., 272, 28073-28080.
29. Weinberg,W.C., Fernandez-Salas,E., Morgan,D.L., Shalizi,A., Mirosh,E., Stanulis,E., Deng,C., Hennings,H. and Yuspa,S.H. (1999) Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res., 59, 2050-2054.
30. Topley,G.I., Okuyama,R., Gonzales,J.G., Conti,C. and Dotto,G.P. (1999) p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc. Natl Acad. Sci. USA, 96, 9089-9094.
31. Barnhart,K.M. and Bowden,G.T. (1985) Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis. Cancer Lett., 29, 101-105.
32. Leopold,W.R., Miller,E.C. and Miller,J.A. (1979) Carcinogenicity of antitumor cis-platinum (II) coordination complexes in the mouse and rat. Cancer Res., 39, 913-918.
33. Hennings,H., Shores,R.A., Poirier,M.C., Reed,E., Tarone,R.E. and Yuspa,S.H. (1990) Enhanced malignant conversion of benign mouse skin tumors by cisplatin. J. Natl Cancer Inst., 82, 836-840.